<clinical_study>
<study_id>
<org_name>
  DiscoveryLabs
</org_name>
<org_full_name>
  Discovery Laboratories
</org_full_name>
<org_study_id>
  KL4-MAS-03
</org_study_id>
<secondary_id>
<id>
  FD-R-001938
</id>
<id_type>
  Other Grant/Funding Number
</id_type>
<id_domain>
  US Department of Health and Human Services
</id_domain>
</secondary_id>
<nct_id>
  NCT00004500
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
</textblock>
</brief_title>
<official_title>
<textblock>
  A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Bronchoalveolar Lavage With Lucinactant to Standard Care for the Treatment of the Meconium Aspriation Syndrome (MAS) in Newborn Infants
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Discovery Laboratories
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  Yes
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  OBJECTIVES:
 
  Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  PROTOCOL OUTLINE:
 
  This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.
 
  Arm I: Patients receive lucinactant by bronchoalveolar lavage, into the right and left lung, followed by lung drainage. Treatment repeats when patient stabilizes or every 15 minutes for 2 courses.
 
  Arm II: Patients receive standard treatment including oxygen, conventional mechanical ventilation, sedation, paralysis, vasopressors, and alkalinization.
 
  Patients are followed for 12 months.
</textblock>
</detailed_descr>
<status_block>
<status>
  Terminated
</status>
<why_stopped>
<textblock>
  Slow enrollment and administrative reasons
</textblock>
</why_stopped>
<date>
2012-05 
</date>
</status_block>
<start_date>
<date>
  2000-03
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2004-11
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2002-11
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Number of Days Receiving Mechanical Ventilation (MV)
</measure>
<time_frame>
  28 days
</time_frame>
<description>
<textblock>
  A patient is not receiving MV if he/she is removed from the mechanical ventilator for &#8805; 24 hours. If a patient subsequently requires intubation and MV, the additional time will count as days receiving MV.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Incidence of Death
</measure>
<time_frame>
  28 days
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
Number of Participants With Air  Leaks  
</measure>
<time_frame>
  28 days
</time_frame>
<description>
<textblock>
  Includes pulmonary interstitial emphysema (PIE), Pneumothorax, Pneumomediastinium, and Pneumopericardium
</textblock>
</description>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  69
</enrollment>
<condition>
  Meconium Aspiration
</condition>
<arm_group>
<arm_group_label>
  Lucinactant
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  Standard Care
</arm_group_label>
<arm_type>
  Other
</arm_type>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Lucinactant
</primary_name>
<description>
<textblock>
  Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant&apos;s body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
</textblock>
</description>
<arm_group_label>
  Lucinactant
</arm_group_label>
<other_name>
  Surfactant
</other_name>
<other_name>
  KL&#8324;Surfactant
</other_name>
</intervention>
<intervention>
<intervent_type>
  Other
</intervent_type>
<primary_name>
  Standard Care
</primary_name>
<description>
<textblock>
  The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
</textblock>
</description>
<arm_group_label>
  Standard Care
</arm_group_label>
<other_name>
  Negative Control
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
-  Diagnosis  of   meconium aspiration syndrome (MAS) 
-   Continuous mechanical ventilation (CMV) at  time  of  entry  
    - Enrollment within 48 hours of birth
    - Gestational age of &#8805; 37 weeks
    - Oxygenation index of &#8805; 5 and &#8804; 30
    - Written informed consent signed and dated by the infant&apos;s parent(s) or legal guardian(s)
 
  Exclusion Criteria:
    - Congenital anomalies likely to affect any primary or secondary endpoints
    - Uncontrollable air leaks
    - Hydrops fetalis
    - Rupture &#8805; 3 weeks of the fetal membranes
    - Evidence of overwhelming bacterial infection at time of randomization
    - Markedly labile persistent pulmonary hypertension at time of randomization
    - Profound neurologic manifestations
    - Sustained postductal SpO&#8322;of &lt; 87% for &#8805; 15 minutes at an FiO&#8322;of 1.00
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
</minimum_age>
<maximum_age>
  48 Hours
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Chair
</role>
<name>
  Thomas E Wiswell
</name>
<affiliation>
<agency>
  Discovery Laboratories, Inc.
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Robert Segal, MD
</name>
<phone>
  215-488-9300
</phone>
<phone_ext>
</phone_ext>
<email>
  rsegal@discoverylabs.com
</email>
</contact>
<location>
<facility>
<name>
  Discovery Laboratories, Inc.
</name>
<address>
<city>
  Warrington
</city>
<state>
  Pennsylvania
</state>
<zip>
  18976
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Terminated
</status>
</location>
<keyword>
  cardiovascular and respiratory diseases
</keyword>
<keyword>
  meconium aspiration syndrome
</keyword>
<keyword>
  rare disease
</keyword>
<initial_release_date>
  1999-10-18
</initial_release_date>
<last_release_date>
2012-05-01 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2012-04-02
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  69
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  38
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &lt;=18 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Between 18 and 65 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &gt;=65 years
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Age Categorical
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  16
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  15
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  38
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  16
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  69
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  38
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  United States
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Region of Enrollment
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  1.21
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  39.9
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  1.30
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  40.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  1.09
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  39.7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  weeks
</unitofmeasure>
<othertitle>
  Gestational Age
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<subjectsanalyzed>
  38
</subjectsanalyzed>
<title>
  Lucinactant
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<subjectsanalyzed>
  31
</subjectsanalyzed>
<title>
  Standard Care
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  69
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  GT60
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
2012-05-01T14:51:00-04:00 
</lastupdatetimestamp>
<limitationsandcaveats>
<description>
<textblock>
  Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.
</textblock>
</description>
</limitationsandcaveats>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  9.96
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10.2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  8.52
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  A patient is not receiving MV if he/she is removed from the mechanical ventilator for &#8805; 24 hours. If a patient subsequently requires intubation and MV, the additional time will count as days receiving MV.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  28 days
</timeframe>
<title>
  Number of Days Receiving Mechanical Ventilation (MV)
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<subjectsanalyzed>
  38
</subjectsanalyzed>
<title>
  Lucinactant
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<subjectsanalyzed>
  31
</subjectsanalyzed>
<title>
  Standard Care
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Data from the initial Phase 1/2 trial were used to estimate the number of subjects required for testing the null hypothesis of no difference between treatment groups. A sample size of 100 subjects per group is required to test the hypothesis at a significance level of 0.05 with a power of 80%.
  All enrolled infants were analyzed (intent-to-treat).
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  28 days
</timeframe>
<title>
  Incidence of Death
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<subjectsanalyzed>
  38
</subjectsanalyzed>
<title>
  Lucinactant
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<subjectsanalyzed>
  31
</subjectsanalyzed>
<title>
  Standard Care
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Data from the initial Phase 1/2 trial were used to estimate the number of subjects required for testing the null hypothesis of no difference between treatment groups. A sample size of 100 subjects per group is required to test the hypothesis at a significance level of 0.05 with a power of 80%.
  All enrolled infants were analyzed (intent-to-treat).
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Includes pulmonary interstitial emphysema (PIE), Pneumothorax, Pneumomediastinium, and Pneumopericardium
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  28 days
</timeframe>
<title>
Number of Participants With Air  Leaks  
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<subjectsanalyzed>
  38
</subjectsanalyzed>
<title>
  Lucinactant
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<subjectsanalyzed>
  31
</subjectsanalyzed>
<title>
  Standard Care
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Data from the initial Phase 1/2 trial were used to estimate the number of subjects required for testing the null hypothesis of no difference between treatment groups. A sample size of 100 subjects per group is required to test the hypothesis at a significance level of 0.05 with a power of 80%.
  All enrolled infants were analyzed (intent-to-treat).
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  Yes
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<title>
  Lucinactant
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<title>
  Standard Care
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  38
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  31
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
</dropwithdrawreasons>
<milestones>
<milestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  24
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  24
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
<titleother>
  1 Year Follow-Up
</titleother>
</milestone>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  0
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  0
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  38
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  31
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
<preassignmentdescription>
</preassignmentdescription>
<recruitmentdetails>
<textblock>
  Recruitment occurred between March 2000 and October 2002. Infants were enrolled from neonatal intensive care units and were randomized to open-label study treatment.
</textblock>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  rsegal@discoverylabs.com
</email>
<organizationname>
  Discovery Laboratories, Inc.
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  215-488-9300
</phonenumber>
<title>
  Dr. Robert Segal
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Anemia NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Disseminated intravascular coagulation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Thrombocyptopenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Bradycardia NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Cardiomegaly NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pulmonary edema NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Tachycardia NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Tricuspid valve incompetence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Congenital, familial and genetic disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Patent ductus arteriosus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Drug withdrawn syndrome
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Oedema NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pyrexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Jaundice NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pneumonia NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Sepsis NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Blood magnesium decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Oxygen saturation decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Feeding disorder NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypocalcemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypoglycemia NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypokalemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hyponatremia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypertonia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypotonia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Oliguria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Renal impairment NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Atlectasis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Bronchopulmonary dysplasia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypoxia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pneumothorax NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pulmonary haemorrhage
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Respiratory failure (exc neonatal)
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Stridor
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Tachypnea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Rash erythematous
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Surgical and medical procedures
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Procedural site reaction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypertension NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypotension NOS
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pulmonary hypertension NOS
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  Lucinactant via bronchoaveolar lavage
</textblock>
</description>
<numsubjectsfrequentevents>
  36
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  23
</numsubjectsseriousevents>
<partatriskfrequentevents>
  38
</partatriskfrequentevents>
<partatriskseriousevents>
  38
</partatriskseriousevents>
<title>
  Lucinactant
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.2"
>
<description>
<textblock>
  Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
</textblock>
</description>
<numsubjectsfrequentevents>
  25
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  14
</numsubjectsseriousevents>
<partatriskfrequentevents>
  31
</partatriskfrequentevents>
<partatriskseriousevents>
  31
</partatriskseriousevents>
<title>
  Standard Care
</title>
</interventiongroup>
</interventiongroups>
<notes>
<textblock>
  AEs followed until resolution or stable condition
</textblock>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Bradycardia NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Cardiac arrest
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Cardiac tamponade
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Cardiomyopathy NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Dysphagia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Drug withdrawal syndrome
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pyrexia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Oxygen saturation decreased
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Acid-base balance disorder mixed
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Feeding Disorder NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Food intolerance NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Renal impariment NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Renal infarct
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Bronchopulmonary dysplasia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypoxia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Meconium aspiration
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pneumothorax NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pulmonary Haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Respiratory failure (exc neonatal)
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Stridor
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypertension NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Hypotension NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Intraventricular haemorrhage NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  38
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  31
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<term>
  Pulmonary hypertension NOS
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
  MedDRA
</sourcevocabulary>
<timeframe>
  28 Days
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
